Profile: Epizyme Inc (EPZM.OQ)
15 Jul 2019
Epizyme, Inc., incorporated on November 1, 2007, is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs).
The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company intends to initiate clinical trials of tazemetostat in combination with other therapies approved for, or being investigated for, the treatment of diffuse large B-cell lymphoma (DLBCL), an aggressive form of NHL. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
The Company discovers and develops inhibitors of CMPs as precision therapeutics for patients with cancer and other significant unmet medical needs. The Company develops pinometostat as an intravenously administered small molecule inhibitor of Disruptor of telomeric silencing 1-like (DOT1L) for the treatment of acute leukemias with alterations in the mixed lineage leukemia (MLL) gene, specifically rearrangements of MLL as a consequence of chromosomal translocation, referred to as MLL-r, which includes partial tandem duplications of the MLL gene, referred to as MLL-PTD. DOT1L is an HMT that can become oncogenic and cause certain subtypes of acute leukemia, such as MLL-r. MLL-r is a genetically-defined subtype of two of the most common forms of acute leukemia, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In addition to tazemetostat and pinometostat, the Company also has a pipeline of small molecule inhibitors in preclinical development that target its other prioritized CMPs. These programs are directed to specific cancers, including both hematological malignancies and solid tumors.
400 Technology Sq Ste 4
CAMBRIDGE MA 02139-3584